-
公开(公告)号：EP2324834B1
公开(公告)日：2019-05-08
申请号：EP10181843.3
申请日：2002-12-06
申请人： Fibrogen, Inc.
发明人： Klaus, Stephen J. , Lin, Al Y. , Neff, Thomas B. , Wang, Qingjian , Guenzler-Pukall, Volkmar , Arend, Michael P. , Flippin, Lee A.
IPC分类号： A61K31/47 , A61K31/4738 , A61K31/63 , A61K31/00 , A61K38/38 , C12N15/09 , C12Q1/56 , C12Q1/34 , A61P7/06 , A61K31/17 , C07K14/47 , C07K14/505 , G01N33/74 , A61K31/472 , A61K31/4745 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/496 , A61K38/17
-
公开(公告)号：EP2289531A3
公开(公告)日：2013-03-13
申请号：EP10181768.2
申请日：2002-12-06
申请人： Fibrogen, Inc.
发明人： Klaus, Stephen J. , Lin, Al Y. , Neff, Thomas B. , Wang, Qingjian , Guenzler-Pukall, Volkmar , Arend, Michael P. , Flippin, Lee A.
IPC分类号： A61K38/00 , C12N15/09 , C12Q1/56 , C12Q1/34 , A61K31/00 , A61K31/47 , A61K31/4738 , A61K31/63 , A61P7/06 , A61K38/17 , C07K14/47 , C07K14/505 , G01N33/74
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/17 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4738 , A61K31/496 , A61K31/63 , A61K38/1709 , C07K14/4702 , C07K14/505 , G01N33/746
摘要： The present invention relates to compounds for use in methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo . Compounds for use in methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included.
-
公开(公告)号：EP2289531A2
公开(公告)日：2011-03-02
申请号：EP10181768.2
申请日：2002-12-06
申请人： FIBROGEN, INC.
发明人： Klaus, Stephen J. , Lin, Al Y. , Neff, Thomas B. , Wang, Qingjian , Guenzler-Pukall, Volkmar , Arend, Michael P. , Flippin, Lee A.
IPC分类号： A61K38/00 , C12N15/09 , C12Q1/56 , C12Q1/34 , A61K31/00 , A61K31/47 , A61K31/4738 , A61K31/63 , A61P7/06
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/17 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4738 , A61K31/496 , A61K31/63 , A61K38/1709 , C07K14/4702 , C07K14/505 , G01N33/746
摘要： The present invention relates to compounds for use in methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo . Compounds for use in methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included.
摘要翻译： 本发明涉及用于通过在体外和体内增加内源促红细胞生成素来治疗促红细胞生成素相关病症的方法中使用的化合物。 还包括用于治疗，预处理或预处理或预防促红细胞生成素相关病症的方法的化合物。
-
4.发明公开Methods of Increasing Endogenous Erythropoietin (EPO) 审中-公开Verfahren zur Steigerung des endogenen红细胞生成素
公开(公告)号：EP2324834A2
公开(公告)日：2011-05-25
申请号：EP10181843.3
申请日：2002-12-06
申请人： Fibrogen, Inc.
发明人： Klaus, Stephen J. , Lin, Al Y. , Neff, Thomas B. , Wang, Qingjian , Guenzler-Pukall, Volkmar , Arend, Michael P. , Flippin, Lee A.
IPC分类号： A61K31/47 , A61K31/4738 , A61K31/63 , A61K31/00 , A61K38/38 , C12N15/09 , C12Q1/56 , C12Q1/34 , A61P7/06
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/17 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4738 , A61K31/496 , A61K31/63 , A61K38/1709 , C07K14/4702 , C07K14/505 , G01N33/746
摘要： The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo . Compounds for treating, pretreating or preconditioning, or preventing neurological disorders are also included.
摘要翻译： 本发明涉及通过在体外和体内增加内源促红细胞生成素来治疗促红细胞生成素相关病症的方法。 还包括用于治疗，预处理或预处理或预防神经障碍的化合物。
-
公开(公告)号：EP2289531B1
公开(公告)日：2018-07-04
申请号：EP10181768.2
申请日：2002-12-06
申请人： Fibrogen, Inc.
发明人： Klaus, Stephen J. , Lin, Al Y. , Neff, Thomas B. , Wang, Qingjian , Guenzler-Pukall, Volkmar , Arend, Michael P. , Flippin, Lee A.
IPC分类号： A61K38/00 , C12N15/09 , C12Q1/56 , C12Q1/34 , A61K31/00 , A61K31/47 , A61K31/4738 , A61K31/63 , A61P7/06 , A61K38/17 , C07K14/47 , C07K14/505 , G01N33/74 , A61K31/472 , A61K31/4745 , A61K31/17 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/496
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/17 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4738 , A61K31/496 , A61K31/63 , A61K38/1709 , C07K14/4702 , C07K14/505 , G01N33/746
摘要： The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
-
公开(公告)号：EP2324834A3
公开(公告)日：2013-02-13
申请号：EP10181843.3
申请日：2002-12-06
申请人： Fibrogen, Inc.
发明人： Klaus, Stephen J. , Lin, Al Y. , Neff, Thomas B. , Wang, Qingjian , Guenzler-Pukall, Volkmar , Arend, Michael P. , Flippin, Lee A.
IPC分类号： A61K31/47 , A61K31/4738 , A61K31/63 , A61K31/00 , A61K38/38 , C12N15/09 , C12Q1/56 , C12Q1/34 , A61P7/06 , A61K38/17 , C07K14/47 , C07K14/505 , G01N33/74
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/17 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4738 , A61K31/496 , A61K31/63 , A61K38/1709 , C07K14/4702 , C07K14/505 , G01N33/746
摘要： The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo . Compounds for treating, pretreating or preconditioning, or preventing neurological disorders are also included.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.01 秒)
